Core B will provide support for all of the animal experiments in Projects 1 and 2 of the proposal. It includes oversight of quality control of ali aspects of animal purchases, maintenance of the animal colony, breeding of mice, UM Unit for Laboratory Animal Medicine regulatory communications, experimental transplantation of mice, and histopathological analysis. It is designed to enhance harmonization and efficiency of the experiments that utilize animals in Projects 1 and 2. The services provided by Core B are: 1. To oversee and monitor adherence to the standards required by the University of Michigan Unit for Laboratory Animal Medicine (ULAM) 2. To facilitate centralized and orderly animal purchases and provide for routine but uniform pretransplant and post-BMT animal care and specialized breeding ofthe knock-out mice 3. To prepare donor cell inoculums and perform BMT following irradiation in a standardized manner 4. To provide supervision for consistent scoring of clinical GVHD in the transplant models 5. To provide standardized harvesting of target organs, processing, staining (hematoxylin and eosin) and shipping of samples for histopathological analysis by Dr. Chen Liu at the University of Florida 6. To provide uniform and consistent histologic analysis of GVHD pathology in target organ tissues

Public Health Relevance

Allogeneic hematopoietic stem cell transplantation is a potentially curative therapy for many malignant diseases whose applicability has been impeded by the development of its most serious complication, GVHD. Strategies that mitigate GVHD will allow for better harnessing of this effective therapeutic modality to treat many patients with hematological cancers.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-J)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Icahn School of Medicine at Mount Sinai
New York
United States
Zip Code
Glick, Gary D; Rossignol, Rodrigue; Lyssiotis, Costas A et al. (2014) Anaplerotic metabolism of alloreactive T cells provides a metabolic approach to treat graft-versus-host disease. J Pharmacol Exp Ther 351:298-307
Choi, Sung Won; Braun, Thomas; Chang, Lawrence et al. (2014) Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: a phase 1/2 trial. Lancet Oncol 15:87-95
Vander Lugt, Mark T; Braun, Thomas M; Hanash, Samir et al. (2013) ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death. N Engl J Med 369:529-39
Harris, Andrew C; Ferrara, James L M; Levine, John E (2013) Advances in predicting acute GVHD. Br J Haematol 160:288-302
MacDonald, Kelli P; Shlomchik, Warren D; Reddy, Pavan (2013) Biology of graft-versus-host responses: recent insights. Biol Blood Marrow Transplant 19:S10-4
Byersdorfer, Craig A; Tkachev, Victor; Opipari, Anthony W et al. (2013) Effector T cells require fatty acid metabolism during murine graft-versus-host disease. Blood 122:3230-7
Levine, John E; Huber, Elisabeth; Hammer, Suntrea T G et al. (2013) Low Paneth cell numbers at onset of gastrointestinal graft-versus-host disease identify patients at high risk for nonrelapse mortality. Blood 122:1505-9
Harris, Andrew C; Kitko, Carrie L; Couriel, Daniel R et al. (2013) Extramedullary relapse of acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation: incidence, risk factors and outcomes. Haematologica 98:179-84
Brown, J R; Kim, H T; Armand, P et al. (2013) Long-term follow-up of reduced-intensity allogeneic stem cell transplantation for chronic lymphocytic leukemia: prognostic model to predict outcome. Leukemia 27:362-9
Paczesny, Sophie (2013) Discovery and validation of graft-versus-host disease biomarkers. Blood 121:585-94

Showing the most recent 10 out of 197 publications